The Diabetes and Endocrine Network has developed a clinical practice guide on the Use of SGLT2-inhibitors for type 2 diabetes in acute inpatient care. The guide outlines the safe use of sodium glucose co-transporter2-inhibitor (SGLT2-i) medicines. It aims to reduce the risk of SGLT2-i-induced diabetic ketoacidosis and improve early recognition and diagnosis of ketoacidosis that may be euglycaemic.
Diabetes and Endocrine Network
31 Oct 2022 Reading time approximately